In mid-February, Inspiration Biopharmaceuticals, Inc., announced the start of a clinical trial for IB1001, a recombinant factor IX (rFIX) product for the control and prevention of bleeding episodes in patients with hemophilia B (factor IX deficiency). The Phase 1 trial will measure the safety, tolerability and pharmacokinetics of the drug.

“The initiation of this Phase 1 trial is an important milestone for the company and for the hemophilia community,” said John Taylor, Chairman and Co-founder, Inspiration Biopharmaceuticals. “This is the first therapy for hemophilia B patients in the past two decades.”

After the trial ends, study participants will then be monitored during a six-month Phase 2/3 trial involving either an on-demand or a prophylatic treatment regimen using IB1001. Inspiration also plans to begin clinical testing of IB1001 in Europe and Israel. The company is based in Laguna Niguel, CA.

Source: Inspiration Biopharmaceuticals, Inc., news release dated February 12, 2009